How China’s strict Covid policies led to supply chain bottlenecks

How China’s strict Covid policies led to supply chain bottlenecks


At the onset of the Covid-19 pandemic, China’s strict “zero-Covid” policies managed to keep Covid-19 at bay. More than two years later, the country’s ongoing controls are still weighing down its economy and stalling global supply chains.

“Zero-Covid has become one of the select drivers of global recession,” Steve Morrison, senior vice president at the Center for Strategic and International Studies, told CNBC in an interview.

Major trade hubs such as Shanghai and Beijing, after responding to waves of omicron-driven infections, require workers to have negative Covid tests to enter public spaces. The demanding quarantine and testing rules have thwarted truckers on roads as well, driving up the amount of time it takes for goods to get to Chinese ports for export.

When it comes to manufacturing, China has forced some companies to operate within a closed-loop system — similar to the “bubble” strategy — where factory workers live on-site. Companies such as Tesla and iPhone manufacturer Foxconn have had to implement closed-loop systems.

That’s not to mention the poor weather, labor challenges and abnormal demand patterns that have also added to supply chain disruptions.

“What supply chains thrive on is predictability,” said Simon Geale, executive vice president of procurement at Proxima, in an interview with CNBC. “And the only thing we can say about China at the moment is that for many businesses, they’re looking at China as being predictably unpredictable.”

Watch the video above to find out how China’s evolving zero-Covid strategies are slowing down global supply chains and whether there’s any relief in sight.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More